All In Biotech

Drug Trial Radar · NCT06389513

Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Phase IV Clinical Study of the Safety of Menhycia® in 3-Month-Old Infants

Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

3,011

Actual

Start

Jun 12, 2024

Primary completion

Apr 10, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
CanSino Biologics Inc.Industry
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 3 months, up to 3 months
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is an open, multicenter Phase IV clinical study to evaluate the safety of vaccination with Menhycia®. The study plan is to enroll approximately 3,000 infants at 3 months of age who have not been vaccinated with any epidemic encephalitis vaccine, and to administer a total of 3 doses of Menhycia®, with a minimum of 1 month between doses, and a booster dose of 1 dose of immunization is allowed at 12 months of age.

Conditions

  • Epidemic Meningitis

Interventions

  • MCV4Biological

    4 doses of vaccine on Day 0, Day30, Day 60 and Month 12

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of localized adverse reactions in subjectsTime frame: Within 7 days after each dose of vaccination
  2. Incidence of systemic adverse reactions in subjectsTime frame: Within 7 days after each dose of vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Nanjing Luhe District Center for Disease Control and Prevention Center for Disease Control and Prevention

    Nanjing, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.